BRIDGEWATER, N.J.--(BUSINESS WIRE)--Neurotez is announcing the appointment of Dr. Lex Van der Ploeg to the Board of Directors. Dr. Van der Ploeg will continue as Chief Scientific Advisor for Neurotez’s development plans, and will now also participate as a member of the Board of Directors. Dr. Van der Ploeg has in depth knowledge in the Neurosciences, Obesity and Oncology, applied through translational research/drug discovery, and drug development efforts at diverse pharmaceutical companies. “Lex’s background and experience are an exceptional fit for Neurotez as we move forward with our clinical efforts. Our primary program to develop Leptin for the treatment of Alzheimer’s disease, and our overarching mission as a biotech, will significantly benefit with Lex on board” said Nikolaos Tezapsidis, President & CEO of Neurotez, Inc. “I am excited about Neurotez’s programs, and the unique mechanisms which Leptin modulates for the treatment of Alzheimer’s disease” stated Lex Van der Ploeg.
